Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primary Tumor Radiotherapy in Stage IV NSCLC with MPE
NCT03987087Phase 2Unknown
- Sponsor
- Guizhou Medical University
- Start
- Sep 2018
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Guizhou Medical University. Primary endpoint: Progression-free survival at 9 months. Status: unknown.
Beyond the preview
Go deeper on NCT03987087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03987087.